TAK-935: Clinical Trials

4 completed, 1 terminated. 5 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	5	Completed 4, Terminated 1
Phase 1	1	Completed 1

Follow TAK-935: new trials by email Literature Review of TAK-935 trials Research Report on TAK-935

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS) Soticlestat, Placebo - Complex Regional Pain Syndrome	Phase 2	Completed	Millennium Pharmaceuticals, Inc.	24	2019-07-23	2026-09-14
A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY) Soticlestat - 15q Duplication Syndrome, CDKL5 Deficiency Disease	Phase 2	Completed	Takeda	20	2018-09-10	2026-09-10
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies TAK-935, Placebo - Epilepsy, Dravet Syndrome	Phase 2	Completed	Takeda	141	2018-08-08	2026-09-14
A Study of Soticlestat in Adults and Children With Rare Epilepsies Soticlestat - Epilepsy, Dravet Syndrome (DS)	Phase 2	Terminated	Takeda	156	2018-07-19	2026-09-04
Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies TAK-935, Placebo - Developmental and/or Epileptic Encephalopathies	Phase 1 / Phase 2	Completed	Takeda	18	2017-08-17	2026-09-14

Conditions studied

Epilepsy (3)  ·  Brain Diseases (2)  ·  CDKL5 deficiency disorder (2)  ·  Central Nervous System Diseases (2)  ·  Epilepsies, Myoclonic (2)  ·  Lennox Gastaut Syndrome (2)  ·  Autistic Disorder (1)  ·  Complex Regional Pain Syndromes (1)  ·  Hypoxia-Ischemia, Brain (1)  ·  Malformations of Cortical Development (1)  ·  Nervous System Diseases (1)  ·  Polyposis Syndrome, Hereditary Mixed, 1 (1)  ·  Seizures (1)  ·  Spasms, Infantile (1)  ·  Tuberous Sclerosis (1)

Sponsors

Takeda (4)  ·  Millennium Pharmaceuticals, Inc. (1)

Countries

United States (4)  ·  Australia (2)  ·  Canada (2)  ·  China (2)  ·  Israel (2)  ·  Poland (2)  ·  Portugal (2)  ·  Spain (2)  ·  United Kingdom (1)

Results publications

PMID 33940389, PMID 35841234, PMID 36538782, PMID 37011526

NIH funding

2018 (2)